Ayal Hendel
Overview
Explore the profile of Ayal Hendel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1958
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Assa G, Kalter N, Rosenberg M, Beck A, Markovich O, Gontmakher T, et al.
Nucleic Acids Res
. 2024 Jul;
52(16):e78.
PMID: 39077930
Off-target effects present a significant impediment to the safe and efficient use of CRISPR-Cas genome editing. Since off-target activity is influenced by the genomic sequence, the presence of sequence variants...
2.
Eisenberg V, Hoogi S, Katzman E, Ben Haim N, Zur-Toledano R, Radman M, et al.
Cancer Immunol Res
. 2024 Jul;
12(10):1380-1391.
PMID: 39037052
Cancer exploits different mechanisms to escape T-cell immunosurveillance, including overexpression of checkpoint ligands, secretion of immunosuppressive molecules, and aberrant glycosylation. Herein, we report that IFNγ, a potent immunomodulator secreted in...
3.
Somekh I, Hendel A, Somech R
JAMA Pediatr
. 2024 May;
178(7):645-646.
PMID: 38767875
No abstract available.
4.
Edri A, Ben-Haim N, Hailu A, Brycman N, Berhani-Zipori O, Rifman J, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139060
Natural killer (NK) cells are a vital component of cancer immune surveillance. They provide a rapid and potent immune response, including direct cytotoxicity and mobilization of the immune system, without...
5.
Cavazza A, Hendel A, Bak R, Rio P, Guell M, Lainscek D, et al.
Mol Ther Nucleic Acids
. 2023 Nov;
34:102066.
PMID: 38034032
The European Cooperation in Science and Technology (COST) is an intergovernmental organization dedicated to funding and coordinating scientific and technological research in Europe, fostering collaboration among researchers and institutions across...
6.
Allen D, Knop O, Itkowitz B, Kalter N, Rosenberg M, Iancu O, et al.
Nat Commun
. 2023 Oct;
14(1):6771.
PMID: 37891182
RAG2-SCID is a primary immunodeficiency caused by mutations in Recombination-activating gene 2 (RAG2), a gene intimately involved in the process of lymphocyte maturation and function. ex-vivo manipulation of a patient's...
7.
Allen D, Kalter N, Rosenberg M, Hendel A
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242571
Genome engineering via targeted nucleases, specifically CRISPR-Cas9, has revolutionized the field of gene therapy research, providing a potential treatment for diseases of the blood and immune system. While numerous genome...
8.
9.
Iancu O, Allen D, Knop O, Zehavi Y, Breier D, Arbiv A, et al.
Mol Ther Nucleic Acids
. 2023 Jan;
31:105-121.
PMID: 36618262
Severe combined immunodeficiency (SCID) is a group of disorders caused by mutations in genes involved in the process of lymphocyte maturation and function. CRISPR-Cas9 gene editing of the patient's own...
10.
Hassin O, Nataraj N, Shreberk-Shaked M, Aylon Y, Yaeger R, Fontemaggi G, et al.
Nat Commun
. 2022 May;
13(1):2800.
PMID: 35589715
The TP53 gene is mutated in approximately 60% of all colorectal cancer (CRC) cases. Over 20% of all TP53-mutated CRC tumors carry missense mutations at position R175 or R273. Here...